Drugs / BG-T187
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06598800 | Oct 2024 → Sep 2028 expected | — | BeOne Medicines | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG-T187 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06598800 ↗ |
| Route | Intravenous | “Phase 1a: Part A: Monotherapy Dose Escalation with Intravenous Administration” NCT06598800 ↗ |
| Target | EGFR | “BG-T187, an EGFR×MET Trispecific Antibody” NCT06598800 ↗ |
| Target | MET | “BG-T187, an EGFR×MET Trispecific Antibody” NCT06598800 ↗ |